NXY-059 does not significantly interact with furosemide in healthy volunteers

Journal of Clinical Pharmacology

Volumn 46, Issue 12, 2006, Pages 1417-1425

  Strid, Stig ^a   Nilsson, Dag ^a   Borgå, Olof ^b   Wemer, Johan ^c   Grahnén, Anders ^d  

^a ASTRAZENECA R AND D   (Sweden)

^b Medical Neuroscience ^*  (Sweden)

^c Xendo Drug Development Services   (Netherlands)

^d IQVIA   (United States)

Author keywords

Acute ischemic stroke; Furosemide; Neuroprotectant; NXY 059; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DISUFENTON SODIUM; FUROSEMIDE; PLACEBO;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACKACHE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSMENORRHEA; FEMALE; HUMAN; KIDNEY CLEARANCE; MALAISE; MALE; MIGRAINE; NAUSEA AND VOMITING; NORMAL HUMAN; PAIN; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SODIUM URINE LEVEL; URINE RETENTION; URINE VOLUME;

EID: 33750697897     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006293372     Document Type: Article

References (17)

1. World Health Organization. The World Health Report 2004. Geneva, Switzerland: The World Health Organization; 2004.
2. American Heart Association. Heart Disease and Stroke Statistics: 2006 Update. Dallas, Tex: American Heart Association; 2006.
3. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
4. Furlan AJ, Katzan IL, Caplan LR. Thrombolytic therapy in acute ischemic stroke. Curr Treat Options Cardiovasc Med. 2003;5:171-180.
5. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjö BK. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab. 1999;19:778-787.
6. Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol. 2002;135:103-112.
7. Marshall JW, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 2001;32:190-198.
8. Marshall JWB, Cummings RM, Bowes LJ, Ridley RM, Green AR. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke. 2003;34:2228-2233.
9. Wang CX, Shuaib A. NXY-059: a neuroprotective agent in acute stroke. Int J Clin Pract. 2004;58:964-969.
10. Lees KR, Zivin JA, Ashwood T, et al: NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
11. Edenius C, Strid S, Borga O, Breitholtz-Emanuelsson A, Vallen KL, Fransson B. Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in healthy young and elderly subjects. J Stroke Cerebrovasc Dis. 2002;11:34-43.
12. Strid S, Borga O, Edenius C, Jostell KG, Odergren T, Weil A. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. Eur J Clin Pharmacol. 2002;58:409-415.
13. Cheng Y-F, Strid S, Borga O, Nilsson D, Wemer J. Effects of cimetidine and probenecid on renal clearance of NXY-059, a novel neuroprotectant: a phase I study to determine the transporter responsible for active secretion. Clin Pharmacol Ther. 2006;79:72.
14. Wakelkamp M, Alvan G, Paintaud G. Natriuretic efficiency of frusemide as a consequence of drug input rate. Br J Clin Pharmacol. 1997;43:481-491.
15. Burg M, Stoner L, Cardinal J, Green N. Furosemide effect on isolated perfused tubules. Am J Physiol. 1973;225:119-124.
16. Werner J, Cheng Y-F, Nilsson D, et al. Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. Curr Med Res Opin. 2006;22:1813-1823.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.